There have been some concerns, however, about the safety of IONIS-TTR Rx and a rival's TTR drug. Glaxo even put its own planned late-stage study of IONIS-TTR Rx on hold after some safety concerns were raised for the drug. Crooke, though, said that IONIS-TTR Rx has an "acceptable safety and tolerability profile" but didn't go into further details.